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Abstract
Background: Several patients with unipolar depression present with prominent dysphoric mood.
We aimed at examining the effectiveness of the combination of an SSRI with an anticonvulsant in
such patients.
Methods: Thirty-five newly admitted outpatients with substantial anger, irritability, aggressiveness
or hostility who were diagnosed a DSM-IV unipolar depressive disorder were rated on the
Hamilton Depression Rating Scale (HDRS), the Clinical Global Improvement (CGI) scale, and a
scale for the rapid dimensional assessment (SVARAD), were prescribed an SSRI and an
anticonvulsant (usually valproate), and were followed up for 12 weeks. Repeated measures analysis
of variance was used to test for within-subject changes in scale scores over time.
Results:  Thirty-two and 23 patients attended the follow-up visits 4 and 12 weeks later,
respectively. Significant decreases (p < .001) were observed in HDRS total score, HDRS and
SVARAD anxiety factors, HDRS and SVARAD core depression factors, and SVARAD anger/
irritability factor. Adjusting for age or gender did not change the results. Most patients (82%) were
rated as improved or much improved on the CGI.
Conclusion: Although our study has several limitations, we observed a remarkable improvement
in most unipolar depressed outpatients with dysphoric mood treated with an SSRI and an
anticonvulsant. The effectiveness of anticonvulsants might be linked to their action on symptoms
of aggression and behavioural activation.
Background
Since many decades, psychopathologists have pointed up
that nonmelancholic and even melancholic depressions
often entail anger [1]. However, until relatively recently,
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there were a scarcity of research findings related to this
issue. This might partly be ascribed to the use of specific
rating scales for depression, which tend to put all depres-
sions 'in the same basket'[2] and have been the object of
some criticisms [3-6]. More recently, the use of compre-
hensive psychopathological rating scales exploring a wide
range of symptoms has enabled several researchers to doc-
ument substantial levels of anger, irritability, hostility and
aggressiveness in a sizable portion of patients with unipo-
lar depression [7-10]. Indeed, anger and aggression are
prominent in depressed patients to a degree that may rival
that of depression and anxiety [11], and anger is higher
among patients with depression compared with patients
with anxiety or somatoform disorders [12,13]. These
patients have particular needs that should be addressed,
and many clinicians share the opinion that antidepressant
medication alone may not be fully adequate. A treatment
approach based on functional/dimensional psychopa-
thology [20,21], might be useful to optimise pharmaco-
logical treatment for these patients. In accordance with
the hypothesised implication of serotonergic pathways in
the brain in aggression [16-18], many authors have sug-
gested that SSRIs might be first choice antidepressants in
patients with depression with hostility [16,19,20]. Other
drugs able to reduce aggressiveness through other bio-
chemical mechanisms, such as some anticonvulsants
affecting the GABAergic and glutammatergic systems,
might also be useful in these patients. However, to our
knowledge, no trial has tested the efficacy of valproate or
other anticonvulsants in the treatment of depression with
dysphoric mood.
In this paper, we report the results of a pilot study where
we examined the effectiveness of the combination of an
SSRI with an anticonvulsant in patients with unipolar
depression with prominent anger, irritability, hostility,
and aggressiveness.
Methods
Patients
The study was performed between March 2002 and May
2004 at the Psychopharmacology Outpatient Clinic of the
Department of Psychiatric Sciences and Psychological
Medicine of the 'La Sapienza' University of Rome. All
patients newly admitted on predetermined weekdays were
considered for enrolment in the study, according to the
following inclusion criteria: a) at least 18 years of age; b)
current diagnosis of a DSM-IV Depressive Disorder, with
the exception of bipolar spectrum conditions (Bipolar
Disorder or Cyclothymic Disorder); c) presence of notable
anger, aggressiveness or hostility as attested by a rating of
1 or higher on the corresponding item of the SVARAD (see
below); d) no comorbid Cluster A Personality disorder or
Borderline Personality Disorder; e) no treatment with
antidepressant drugs in the preceding 2 months; f)
absence of severe physical illness. A total of 35 consecu-
tive patients meeting these criteria were included in the
study. Their demographic and clinical characteristics are
summarised in Table 1.
Procedure
At admission, all patients underwent a careful psychiatric
examination lasting about 90 minutes, and then were
diagnosed according to DSM-IV criteria. All diagnoses
were confirmed by a faculty psychiatrist with more than
25 years of clinical experience who reviewed all clinical
records. Also, patients were rated on the 17-item Hamil-
ton Depression Rating Scale (HDRS) [21], and the
SVARAD. The SVARAD (acronym for the Italian name
'Scala per la VAlutazione RApida Dimensionale', i.e. scale
for rapid dimensional assessment) is a 10-item instru-
ment specifically developed for the rapid assessment of
the main psychopathological dimensions [22]. A valida-
tion study has documented interrater reliability, content
validity, and criterion validity [22]. The items explore the
following dimensions: 1) apprehension/fear; 2) sadness/
demoralization; 3) anger/aggressiveness; 4) obsessive-
ness; 5) apathy; 6) impulsivity; 7) reality distortion; 8)
thought disorganization; 9) somatic preoccupation/
somatization; 10) activation. Item 3 is defined as follows:
irritation, anger, resentment; irritability, litigiousness,
hostility; verbal or physical violence. The items are rated
on a 5-point scale ranging from 0 to 4, with higher scores
indicating greater severity. All raters had great familiarity
with this instrument and had been trained in its proper
use.
All patients were prescribed a Selective Serotonin
Reuptake Inhibitor (SSRI) and an anticonvulsant effective
on symptoms of aggression and behavioural activation,
and were instructed to come back to the outpatients clinic
at regular intervals for follow-up visits. For each patient,
medication was chosen by the treating psychiatrist openly
without any fixed schemata and according to clinical
impression. Drug dosages were titrated individually.
Details about drug treatment are reported in Table 1. After
4 and 12 weeks, patients were rated again on the HDRS
and the SVARAD. In addition, they were rated on the Glo-
bal Improvement item of the Clinical Global Improve-
ment (CGI) scale [27].
Data reduction and statistical analysis
There is ample evidence that the HDRS is not unidimen-
sional [2]. While the number of factors identified ranges
widely, there is strong support for the presence a 'core
depression' factor and an 'anxiety' factor, as well as for a
sleep disturbance factor. According to the results of a
recent confirmatory factor analysis [23], which shared
many similarities with a previous study by our group [24],
the 'core depression' factor is loaded by items 1, 7 and 8Clinical Practice and Epidemiology in Mental Health 2007, 3:3 http://www.cpementalhealth.com/content/3/1/3
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(depressed mood, work and activities, retardation), while
the 'anxiety' factor is loaded by items 10, 11, and 15 (psy-
chic anxiety, somatic anxiety, hypochondriasis). Hence,
for the HDRS, we calculated the scores on these two sub-
sets of items in addition to the total score for each time
point. Also, given the potential risk of deliberate self-harm
in these patients we analysed separately the HDRS item on
suicide.
As regards the SVARAD, two studies on depressed patients
[10,25] have consistently shown three factors, namely an
"anger/irritability" dimension (anger/aggressiveness,
impulsivity, and activation), a "pure depression" dimen-
sion (sadness/demoralization, apathy), and an "anxiety"
dimension (apprehension/fear, somatic preoccupation/
somatization). Therefore, scores on these three factors
were calculated for each time point.
Repeated measures analysis of variance (ANOVA) was
used to test for within-subject changes in scores on the
HDRS and the SVARAD over time. Greenhouse-Geisser
correction was used to adjust degrees of freedom for all F
tests if Mauchly's test of sphericity indicated heterogeneity
of covariances. All ANOVAs yielding significant results
were performed again adjusting for gender and age (≤ 45
vs. > 45 years) in two separate models. Given that the
number of patients receiving some drugs was too small to
build ANOVA models adjusting for the prescribed antide-
pressant or anticonvulsant, the findings were stratified by
medication type in order to visually inspect whether the
changes over time in outcome measures were consistent
across strata. Change in scores on the HDRS suicide item
were tested with Wilcoxon's nonparametric test.
Results
Thirty-two and 23 patients attended the follow-up visits 4
and 12 weeks later, respectively. There was a substantial
and highly significant (p < .001) decrease in the CGI
score, HDRS total score, HDRS and SVARAD anxiety fac-
tors, HDRS and SVARAD core depression factors, and
Table 1: Demographic and clinical characteristics of patients
Gender 12 males (34%)
23 females (66%)
Age (mean ± SD) 44.6 ± 11.7
Main diagnosis Major Depressive Disorder 27 (77%)
Dysthymic Disorder 4 (11%)
Depressive Disorder NOS 3 (9%)
Adjustment Disorder with Depressed Mood 1 (3%)
Psychiatric comorbidity No comorbid axis I or II disorder 27 (77%)
Panic Disorder 2 (6%)
Generalised Anxiety Disorder 1 (3%)
Bulimia Nervosa 1 (3%)
Eating Disorder NOS 1 (3%)
Conversion Disorder 1 (3%)
Histrionic Personality Disorder 1 (3%)
Dependent Personality Disorder 1 (3%)
HDRS baseline score (mean ± SD) 17.3 ± 3.3
Antidepressant drug prescribed Paroxetine 11 (31%)
(mean dose 24 mg/die, range 20–30)
Fluvoxamine 10 (29%)
(mean dose 125 mg/die, range 100–250)
Citalopram 10 (29%)
(mean dose 29 mg/die, range 20–40)
Fluoxetine 2 (6%)
(both patients on 20 mg/die)
Sertraline 2 (6%)
(mean dose 125 mg/die, range 100–150)
Anticonvulsant prescribed Valproate 26 (74%) (mean dose 438 mg/die, range 200–1000)
Carbamazepine 3 (9%)
(mean dose 550 mg/die, range 450–600)
Gabapentin 6 (17%)
(mean dose 517 mg/die, range 300–600)
Legend: HDRS = Hamilton Depression Rating ScaleClinical Practice and Epidemiology in Mental Health 2007, 3:3 http://www.cpementalhealth.com/content/3/1/3
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SVARAD anger/irritability factor (Table 2, Figures 1, 2). At
the 12-week follow-up visit, most patients (82%) were
rated as 'improved' or very much improved' on the Global
Improvement item of the CGI. Similarly, 80% of patients
experienced a reduction in HDRS total score of at least
35%. In most patients the HDRS total score decreased to
levels indicating remission (0–7; 35%) or only mild
depression (8–13; 50%).
On a percentage basis, the improvement was most pro-
nounced in anger/irritability, marked in depressed mood,
and moderate in anxiety. The observed improvement
remained highly significant (p < .001 for all outcome
measures) when adjusting for either gender or age. Also,
when we stratified patients according to the prescribed
antidepressant (paroxetine, fluvoxamine, or citalopram)
or anticonvulsant, the improvement was consistent across
strata on all outcome measures. Suicidal ideation was
present in 12 (34%), 5 (23%), and zero patients at base-
line, 4 weeks, and 12 weeks, respectively. The change in
scores over time on the HDRS suicide items was highly
significant (p = 0.005).
Conclusion
This study has several limitations, including the lack of a
placebo control group and the absence of control groups
treated with only an SSRI or only an anticonvulsant. The
lack of a control group treated with only one active drug
Table 2: Changes in outcome measures over time
Outcome measure Baseline
(mean ± SD)
4 weeks
(mean ± SD)
12 weeks
(mean ± SD)
HDRS total score* 17.3 ± 3.3 (n = 35) 12.9 ± 3.7 (n = 32) 9.3 ± 3.9 (n = 20)
HDRS Core depression factor* 4.8 ± 1.4 (n = 35) 3.4 ± 1.5 (n = 32) 2.1 ± 1.3 (n = 20)
HDRS Anxiety factor* 3.6 ± 1.5 (n = 35) 3.1 ± 1.3 (n = 32) 2.3 ± 1.0 (n = 20)
SVARAD Core depression factor* 3.5 ± 1.2 (n = 35) 2.2 ± 1.2 (n = 32) 1.1 ± 1.0 (n = 23)
SVARAD Anxiety factor* 3.1 ± 1.3 (n = 35) 2.4 ± 1.2 (n = 32) 2.0 ± 1.5 (n = 23)
SVARAD Anger/irritability factor* 3.2 ± 1.5 (n = 35) 1.7 ± 1.2 (n = 32) 1.0 ± 0.8 (n = 23)
* p < 0.001
Significant decrease of SVARAD from baseline to 4 and 12 weeks Figure 1
Significant decrease of SVARAD from baseline to 4 and 12 weeks. SV-D = SVARAD-Depresseive Factor; SV-A = SVARAD-
Anxiety Factor; SV-Ang = SVARAD-Anger/irritability factor. * Values were significant for p < 0.001
0
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precludes firm conclusions about the advantages of com-
bined treatment over monotherapy. Also, our decision to
use various SSRIs and anticonvulsants rather than a single
drug in each class might be criticised, although it more
closely resembles daily clinical practice. Further, while
dropout was very limited (9%) at 4 weeks, follow-up data
were not available for 34% of patients at 12 weeks. Usu-
ally, drop-outs occur for reasons such as lack of efficacy,
adverse effect, or improvement. Unfortunately, we did not
systematically investigated dropouts and cannot tell how
many of these patients were unsatisfied with treatment.
However, even a sensitivity analysis assuming a worst-case
scenario (i.e., all drop-outs due to inefficacy or adverse
effects) would still yield a percentage of patients rated as
'improved' or 'much improved' on the CGI as high as
54%. Moreover, the outcome was not independently
assessed, because the raters were involved in the treatment
of each patient. However, most patients were seen by two
clinicians who both participated in the completion of the
rating scales, and this should have reduced the risk of
assessment bias.
While these limitations suggest great caution in interpret-
ing the results of the present study and dictate the need of
a replication on a larger sample with a controlled design,
we observed that most unipolar depressed outpatients
with dysphoric mood improved quickly when treated
with an SSRI combined with an anticonvulsant. The use of
the SVARAD, an assessment instrument covering a broad
range of psychopathological dimensions, enabled us to
detect a rapid and marked improvement not only in the
depressive and anxiety dimensions, but also in the anger/
irritability dimension. The average percentage of improve-
ment on the anger/irritability dimension was 69%, while
the average percentage of improvement on the depressive
and anxiety dimensions was 56% and 36% on the HDRS
and 69% and 35% on the SVARAD, respectively. While
the selection of patients with high pre-treatment levels of
anger/irritability may partly account for the greater
improvement observed in this dimension, these findings
suggest that the HDRS is less well suited to document
improvement in depressed patients with dysphoric mood,
because it contains many items tapping the relatively less
responsive anxiety symptoms, while it includes no items
exploring the anger/irritability dimension.
These findings suggest that adding valproate and possibly
other anticonvulsants to antidepressant medication might
be a profitable strategy not only in bipolar depression, but
also when dealing with unipolar depressed patients pre-
senting with prominent symptoms of anger, irritability,
and hostility. Although our patients were not assessed
using a structured diagnostic interview, the diagnoses
were made after a careful psychiatric examination, and
were confirmed by a very experienced faculty psychiatrist
who reviewed all clinical records. While apparent unipo-
lar depression might turn out to be bipolar II disorder on
careful questioning [26] and some bipolar patients are
misdiagnosed as unipolar [27], the clinicians involved in
the study had been instructed to inquire about a history of
mood swings, hypomania or mania, and this precaution
should have minimised, though not ruled out, the risk of
misdiagnosis. Indeed, only two patients had a clinically
relevant score on item 10 which taps symptoms of behav-
ioural activation or mood elevation. Also, it should be
noted that prominent dysphoria in a depressed patient
should not be taken as synonymous with bipolar depres-
sion or mixed state derived from the combination of
depressive and manic symptoms. Several studies have
documented that anger, irritability, and hostility can be
Significant decrease of Hamilton-D Rating Scale from baseline to 4 and 12 weeks Figure 2
Significant decrease of Hamilton-D Rating Scale from baseline to 4 and 12 weeks. HDRS = Hamilton-D Rating Scale Total 
Score; HD-D = Ham-D Depressive factor. HD-A: Ham-D Anxiety Factor. * Values were significant for p < 0.001
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present in unipolar patients, while the Vienna school of
psychopathology has even suggested that dysphoria
should be regarded as a third mood quality separated
from depression and mania [28]. In this view, a dimen-
sional approach to diagnosis might help designing a
pathogenesis-oriented diagnosis in the tradition of Kret-
schmer [29]. While nosological disputes are beyond the
scope of this paper, the nosology of mixed states has sev-
eral limitations that have been underlined in an extensive
review [30].
The relationship between aggressive behaviour and
reduced serotonergic activity in the central nervous system
has led several authors to suggest serotonergic treatment
for psychiatric conditions with prominent anger or aggres-
sion. Previous studies did not observe a preferential
response to SSRIs compared to other antidepressants in
depressed patients with hostility [9,31]. Unfortunately,
the design of our study does not permit us to disentangle
the relative contribution of SSRIs to improvement.
In our study, the large majority of patients (74%) received
valproate in addition to serotonergic treatment. Only a
few patients received carbamazepine (9%), while some
were prescribed gabapentin (17%). Hence, our findings
apply mostly to valproate. Whereas its efficacy in acute
mania [32] and possibly in the long-term maintenance
treatment of bipolar disorder [33] is supported by double-
blind placebo controlled trials, there are no controlled tri-
als on its efficacy in depression with dysphoric mood.
Interestingly, there is no agreed definition of the term
'mood stabiliser'. Possibly, the use of a strictly categorical
approach to diagnosis in clinical trials might obscure
some pharmacological effects that are nevertheless clini-
cally important in everyday practice, where one has to
deal with those symptom clusters that are prominent in a
given patient rather than with a categorical diagnosis. In
this regard, it should be emphasised that we used val-
proate because to its documented effectiveness on symp-
toms of aggression and behavioural activation, rather
than due to its still controversial mood stabilising proper-
ties.
As long suggested [34,15], overcoming the reductive strat-
egy of prescribing psychotropic drugs based on a strict
matching of drugs with diagnostic categories might per-
mit to explore new strategies, such as treatments based on
the specific pathophysiologic mechanisms of those symp-
tom clusters or psychopathological dimensions that are
relevant in each patient. A possible mechanism of action
of some anticonvulsants in reducing hostile behaviours
and anger could arise from their effects on the GABAergic
system. For instance, valproate treatment results in
increased GABA levels, inhibition of GABA catabolism,
increase of postsynaptic GABA responses, and blockade of
sodium channels implying a reduction of the glutamate
response [34]. Carbamazepine has a tricyclic structure,
with some GABAergic and antiglutamatergic effects, while
gabapentin appears to have more subtle GABAergic effects
such as increasing glial GABA release and action on GABA
transporters [35]. Interestingly, irritability has been the
most consistently differentiating symptom favouring val-
proate benefit in patients with disorders other than bipo-
lar disorder [36,37].
In conclusion, depression with dysphoric mood may be
regarded as a particular depressive condition that requires
specific management. The proper identification of symp-
toms such as intense anger, irritability, hostility, and
aggressiveness in a depressed patient is clinically impor-
tant and has substantial implications for treatment. In
spite of several limitations, this study showed a significant
and rapid improvement not only in depressive and anxi-
ety symptoms, but also in anger, irritability and hostility
in unipolar depressive outpatients following a short
course of treatment with a combination of an SSRI and an
anticonvulsant, mostly valproate. If our results were con-
firmed, they would confirm the advantages of using a
dimensional rather than a strictly categorical approach to
psychopathological assessment and treatment of psychiat-
ric conditions. Clearly, future studies with more robust
methodology are needed to corroborate our findings.
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